Vlado Perkovic's Publications
About Vlado Perkovic's Publications
Board Member- MBBS,
- PhD,
- FASN,
- FRACP
-
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
Clinical Journal of the American Society of Nephrology Date published: -
Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium
BMJ Date published: -
Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial
Date published: -
An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes
Date published: -
Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program
Date published: -
The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme
Date published: -
DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM
Date published: -
RESIDUAL LIFETIME FRACTURE RISKS AND YEARS OF LIFE LOSS DUE TO OSTEOPOROSIS IN THE AUSTRALIAN POPULATION: AN APPLICATION OF AN OS'T'EOPOROSIS HEALTH ECONOMIC MODEL
Date published: -
Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER
Date published: -
EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER
Date published: -
EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS
Date published: -
EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER
Date published: -
First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease
Date published: -
Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial
Date published: -
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
JAMA: The Journal of the American Medical Association Date published: -
SGLT2 inhibitor lowers risk of kidney failure in type 2 diabetes
Pharmaceutical Journal Date published:
